Evaluation of Cardiovascular Risk Markers in Psoriasis Patients Treated With Secukinumab
Status:
Completed
Trial end date:
2016-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study was to explore the effect of treatment with 300 mg or with 150 mg
secukinumab (administered weekly for 4 weeks followed by four-weekly administration) on
endothelial dysfunction and arterial stiffness after 12 weeks and for up to 52 weeks in
subjects with chronic plaque-type psoriasis. Furthermore soluble biomarkers were assessed to
evaluate the influence of secukinumab on cardiovascular risk. Magnetic resonance imaging
(MRI) was performed in a sub-population to assess the treatment effect on arterial vessel
wall morphometry in atherosclerosis prone vascular beds.